<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04420624</url>
  </required_header>
  <id_info>
    <org_study_id>7727</org_study_id>
    <nct_id>NCT04420624</nct_id>
  </id_info>
  <brief_title>COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction</brief_title>
  <acronym>COLD-MI</acronym>
  <official_title>COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the benefit of colchicine on induced denervation after myocardial
      infarction. Patients who have suffered a documented De Novo myocardial infarction and
      completed a revascularization procedure will receive either colchicine on top of standard
      therapy, compared to standard therapy alone (1:1 allocation ratio). Colchicine 1mg (or 0.5mg)
      will be initiated within 48h after percutaneous revascularization and prescribed for one
      month.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COLD-MI study aims to explore colchicine's impact on myocardial denervation following
      reperfused acute myocardial infarction. Acute myocardial infarction is the leading cause of
      heart failure (HF). It induces myocardial denervation predisposing to ventricular rhythm
      disorders and death. This denervation linked to infarction's size occurs by direct ischaemic
      mechanisms during the initial coronary occlusion (initially non-vascularised zone) and
      secondarily by cardiac remodelling in the context of the heart failure (HF). In usual
      practice, cardiac denervation which intensity is correlated with rhythm and mortality risks,
      can be evaluated by scintigraphy. In a murine reperfusion model of ischemia, the direct
      anti-inflammatory effect of colchicine reduces the size of the necrosis and improves
      post-ischemic remodeling. This suggests that colchicine may reduce myocardial denervation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, phase IIb, monocentric, randomized, open labeled with 2 parallel study arms.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of myocardial denervation</measure>
    <time_frame>6 month</time_frame>
    <description>assess by MIBG (méta-iodobenzylguanidine)-nuclear cardiac imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the heart-to-mediastinum ratio</measure>
    <time_frame>6 month</time_frame>
    <description>The heart-to-mediastinum (H/M) ratio, the heart count normalized for the mediastinum count, is used as a quantitative index in cardiac 123 I-MIBG imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction in percent</measure>
    <time_frame>6 month</time_frame>
    <description>By transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction in percent</measure>
    <time_frame>6 month</time_frame>
    <description>By MIBG (méta-iodobenzylguanidine)-nuclear cardiac imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction in percent</measure>
    <time_frame>1 month</time_frame>
    <description>By transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sinus variability</measure>
    <time_frame>6 month</time_frame>
    <description>by 24 hours holter recording : SDNN (Standard Deviation of NN intervals) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sinus variability</measure>
    <time_frame>1 month</time_frame>
    <description>by 24 hours holter recording : SDNN (Standard Deviation of NN intervals) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic ECG parameters (QRS duration)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic ECG parameters (QRS duration)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic ECG parameters (corrected QT)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic ECG parameters (corrected QT)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular extrasystole (2 or 3 VES) per 24 hours on the Holter</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bursts (2 or 3 VES) per 24 hours on the Holter</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bursts (2 or 3 VES) per 24 hours on the Holter</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular or supraventricular tachycardia (&gt;3 VES) episodes per 24 hours</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular or supraventricular tachycardia (&gt;3 VES) episodes per 24 hours</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to death (total mortality)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to heart failure hospitalization</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to all-cause hospitalization</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between hospitalization and 1 month</time_frame>
    <description>Concentration of NGF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between 1 month and 6 months</time_frame>
    <description>Concentration of NGF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between hospitalization and 1 month</time_frame>
    <description>Concentration of proNGF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between 1 month and 6 months</time_frame>
    <description>Concentration of proNGF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between hospitalization and 1 month</time_frame>
    <description>Concentration of BDNF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between 1 month and 6 months</time_frame>
    <description>Concentration of BDNF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological evaluation of infarction size Creatine PhosphoKinase (CPK)</measure>
    <time_frame>During hospitalization (Day 1 to Day 5)</time_frame>
    <description>Area Under Curve (AUC) of CPK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological evaluation of infarction size (troponin)</measure>
    <time_frame>During hospitalization (Day 1 to Day 5)</time_frame>
    <description>Area Under Curve (AUC) of Troponin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post infarction systemic inflammation evaluation</measure>
    <time_frame>Between hospitalization and 1 month</time_frame>
    <description>Concentration of biomarkers from blood : CRP (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post infarction systemic inflammation evaluation</measure>
    <time_frame>Between 1 month and 6 months</time_frame>
    <description>Concentration of biomarkers from blood : CRP (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post infarction systemic inflammation evaluation</measure>
    <time_frame>Between hospitalization and 1 month</time_frame>
    <description>Concentration of biomarkers from blood : sST2 (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post infarction systemic inflammation evaluation</measure>
    <time_frame>Between 1 month and 6 months</time_frame>
    <description>Concentration of biomarkers from blood : sST2 (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size in percentage of left ventricular</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse event</measure>
    <time_frame>from randomization to 6 months</time_frame>
    <description>Comparison of adverse events between 2 arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Myocardial Infarction, Acute</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>colchicine and standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month</description>
    <arm_group_label>Colchicine</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 80 year old

          -  Hospitalization within 12 hours of onset of acute chest pain

          -  Patient must have suffered a documented acute myocardial infarction

          -  Coronary occlusion on initial angiography (culprit artery with aTIMI (Thrombolysis in
             Myocardial Infarction) flow 1 or 0)

          -  Patient eligible for a revascularization procedure by PTCA (Percutaneous transluminal
             coronary angioplasty)

        Exclusion Criteria:

          -  Patients with a history of myocardial infarction prior to the current episode

          -  Patient in cardiogenic shock or with hemodynamic instability

          -  Patients with severe hepatic or renal dysfunction (GFR ≤30 mL/min)

          -  Pregnant women or women of childbearing age without contraception

          -  Treatment with a potent CYP3A4 inhibitor or a P-glycoprotein inhibitor in patients
             with renal or hepatic impairment or an HMGCoA reductase inhibitor

          -  Association with macrolides (except spiramycin)

          -  Association with pristinamycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myriam AKODAD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myriam AKODAD, MD, PhD</last_name>
    <phone>0033467332501</phone>
    <email>m-akodad@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabien HUET, MD, MsC</last_name>
    <phone>0033467332501</phone>
    <email>f-huet@chu-montpellier.fr</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Sympathetic denervation</keyword>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

